PURPOSE: To determine the rate of posterior capsule opacification (PCO) in eyes with an Akreos Adapt or Akreos Fit intraocular lens (IOL) (Bausch & Lomb) over a minimum follow-up of 18 months. SETTING: Department of Ophthalmology, Worthing and Southlands Hospital NHS Trust, Worthing, United Kingdom. METHOD: This was a retrospective analysis of 102 patients who had uneventful phacoemulsification with implantation of an Akreos Adapt IOL or Akreos Fit IOL from September 2001 to May 2004. Patients from a single surgeon's operating list were recruited into the study. Exclusion criteria included posterior subcapsular cataract, history of uveitis, diabetic retinopathy, glaucoma, and age-related macular degeneration. The protocol included the determination of logMAR best corrected visual acuity (BCVA) and PCO scoring using the Evaluation of Posterior Capsular Opacification System (EPCO 2000) by digital photography of the posterior capsule. The number of patients having a neodymium:YAG (Nd:YAG) capsulotomy was also recorded. RESULTS: The mean follow-up was 30 months +/- 10.3 (SD). The mean BCVA was 20/32 (0.2 logMAR). The mean EPCO score at the central 6.0 mm of the posterior capsule was 0.39 +/- 0.53 and at the central 3.0 mm, 0.18 +/- 0.40. The Nd:YAG capsulotomy rate was 8.8%. CONCLUSIONS: All patients had stable visual acuity with low rates of PCO 2.5 years after surgery. The PCO rate with the Akreos IOL was similar to that with other acrylic IOLs reported in the literature.
PURPOSE: To determine the rate of posterior capsule opacification (PCO) in eyes with an Akreos Adapt or Akreos Fit intraocular lens (IOL) (Bausch & Lomb) over a minimum follow-up of 18 months. SETTING: Department of Ophthalmology, Worthing and Southlands Hospital NHS Trust, Worthing, United Kingdom. METHOD: This was a retrospective analysis of 102 patients who had uneventful phacoemulsification with implantation of an Akreos Adapt IOL or Akreos Fit IOL from September 2001 to May 2004. Patients from a single surgeon's operating list were recruited into the study. Exclusion criteria included posterior subcapsular cataract, history of uveitis, diabetic retinopathy, glaucoma, and age-related macular degeneration. The protocol included the determination of logMAR best corrected visual acuity (BCVA) and PCO scoring using the Evaluation of Posterior Capsular Opacification System (EPCO 2000) by digital photography of the posterior capsule. The number of patients having a neodymium:YAG (Nd:YAG) capsulotomy was also recorded. RESULTS: The mean follow-up was 30 months +/- 10.3 (SD). The mean BCVA was 20/32 (0.2 logMAR). The mean EPCO score at the central 6.0 mm of the posterior capsule was 0.39 +/- 0.53 and at the central 3.0 mm, 0.18 +/- 0.40. The Nd:YAG capsulotomy rate was 8.8%. CONCLUSIONS: All patients had stable visual acuity with low rates of PCO 2.5 years after surgery. The PCO rate with the Akreos IOL was similar to that with other acrylic IOLs reported in the literature.